+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Myeloproliferative Disorders Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 89 Pages
  • December 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5303674

Quick Summary:

In a rapidly evolving healthcare industry where precision and efficacy are paramount, understanding the nuances of the global Myeloproliferative Disorders Drugs Market is a necessity for business executives aiming to stay ahead of the curve. Our comprehensive research report on this market, currently valued at an estimated US$9.3 Billion in 2022, provides insightful analysis and detailed insights into the future trajectory of this market, which is projected to reach around US$12.9 Billion by 2030.

Key features of this report include sharp analysis of key market segments like Ph+ Chronic myelogenous leukemia (CML), which is forecasted to record a 3.5% CAGR and reach US$9.2 Billion by 2030. Additionally, it offers a robust evaluation of emerging markets, with special focus on China, poised to grow at 7.3% CAGR. With a sweeping overview of market competitiveness and presence across various geographies, our report provides valuable information for decision-makers and strategists.

Global Myeloproliferative Disorders Drugs Market to Reach $12.9 Billion by 2030

The global market for Myeloproliferative Disorders Drugs estimated at US$9.3 Billion in the year 2022, is projected to reach a revised size of US$12.9 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2022-2030. Ph+ Chronic myelogenous leukemia (CML), one of the segments analyzed in the report, is projected to record 3.5% CAGR and reach US$9.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ph- Myeloproliferative Neoplasms (MPNs) segment is readjusted to a revised 6.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2.5 Billion, While China is Forecast to Grow at 7.3% CAGR

The Myeloproliferative Disorders Drugs market in the U.S. is estimated at US$2.5 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.9% and 3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Select Competitors (Total 34 Featured) -

  • Bristol-Myers Squibb
  • Inctye
  • Novartis
  • Pfizer
  • Takeda
  • Teva

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Myeloproliferative Disorders Drugs

What is the estimated value of the Global Market for Myeloproliferative Disorders Drugs?

The Global Market for Myeloproliferative Disorders Drugs was estimated to be valued at $9.3 Billion in 2022.

What is the growth rate of the Global Market for Myeloproliferative Disorders Drugs?

The growth rate of the Global Market for Myeloproliferative Disorders Drugs is 4.2%, with an estimated value of $12.9 Billion by 2030.

What is the forecasted size of the Global Market for Myeloproliferative Disorders Drugs?

The Global Market for Myeloproliferative Disorders Drugs is estimated to be worth $12.9 Billion by 2030.

Who are the key companies in the Global Market for Myeloproliferative Disorders Drugs?

Key companies in the Global Market for Myeloproliferative Disorders Drugs include Bristol, Myers Squibb, Inctye, Novartis, Pfizer, Takeda and Teva.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Impact of Covid-19 and a Looming Global Recession
  • Myeloproliferative Disorders Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 10: World Myeloproliferative Disorders Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 11: USA Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 12: USA Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 13: USA 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
CANADA
  • Table 14: Canada Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 15: Canada Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 16: Canada 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
JAPAN
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 17: Japan Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 18: Japan Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: Japan 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
CHINA
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 20: China Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: China Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: China 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
EUROPE
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 23: Europe Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 24: Europe Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: Europe 16-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 26: Europe Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: Europe Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: Europe 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
FRANCE
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 29: France Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: France Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: France 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
GERMANY
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 32: Germany Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: Germany Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: Germany 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
ITALY
  • Table 35: Italy Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Italy Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: Italy 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
UNITED KINGDOM
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 38: UK Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: UK Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: UK 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
SPAIN
  • Table 41: Spain Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: Spain Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Spain 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
RUSSIA
  • Table 44: Russia Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Russia Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Russia 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
REST OF EUROPE
  • Table 47: Rest of Europe Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Rest of Europe Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: Rest of Europe 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
ASIA-PACIFIC
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 50: Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 51: Asia-Pacific Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: Asia-Pacific 16-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
  • Table 53: Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: Asia-Pacific Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: Asia-Pacific 16-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2014, 2023 & 2030
AUSTRALIA
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bristol-Myers Squibb
  • Inctye
  • Novartis
  • Pfizer
  • Takeda
  • Teva